Diabetes remains one of the most significant health problems in the world. Substantial effort has been made to catch diabetes early and adhere to evidence-based practice in an effort to decrease the incidence of the disease and prevent a myriad of diabetes-related complications. Despite our best efforts as clinicians, the incidence of diabetes in the United States of America has not declined since 2000.1
A prediabetic state has been recognized by the Centers for Disease Control and Prevention largely in an effort to intervene before clinical type 2 diabetes has developed. The goal of early recognition of those at risk for type 2 diabetes is to promote a healthy lifestyle through diet, exercise, and weight loss in the hopes of preventing or delaying clinical diabetes and the cardiovascular consequences of elevated blood glucose levels.
Various blood tests would indicate prediabetes or diabetes.
The Goodbody Health Group Inc. is listed on the Canadian Securities Exchange (CSE), the Aquis Stock Exchange – Growth Market (AQSE) Apex segment, OTC Pink, and Frankfurt Stock Exchange (FSE), providing current and prospective shareholders with multiple platforms in which to buy and sell Goodbody Health Group Inc. stock under the EPIC codes: CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: GDBYF).